Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
63
Recruiting, industry sponsors, Respiratory, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed931
63 trials
Showing 1 to 25, recently updated first.
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06878261 · 990 participants (planned) · Start Mar 25, 2025 · Primary completion Mar 13, 2029
Drug: Tezepelumab · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 285 sites in all
PfizerPfizer (PFE)
NCT07839884 · 1,360 participants (planned) · Start Oct 14, 2026 · Primary completion Apr 21, 2034
Drug: Tilrekimig · For: Moderate to Severe Chronic Obstructive Pulmonary Disease
Sites: San Diego, California; Winston-Salem, North Carolina; DuBois, Pennsylvania
- A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)Pivotal-lookingRecruiting
Generate BiomedicinesIndustry
NCT07359846 · 786 participants (planned) · Start Jan 20, 2026 · Primary completion Jan 2029
Drug: GB-0895; Placebo · For: Severe Asthma
Sites: Bakersfield, California; Inglewood, California; Lancaster, California · 166 sites in all
- A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07780669 · 624 participants (planned) · Start Aug 27, 2026 · Primary completion Jul 20, 2029
Drug: GSK5784283; Placebo and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Doral, Florida; Derby, Kansas; Lake Charles, Louisiana · 11 sites in all
- eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07177339 · 1,196 participants (planned) · Start Oct 20, 2025 · Primary completion Apr 2, 2029
Drug: Depemokimab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Sheffield, Alabama; Tucson, Arizona; Escondido, California · 293 sites in all
- Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07190209 · 942 participants (planned) · Start Sep 16, 2025 · Primary completion Nov 27, 2029
Drug: Lunsekimig; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Chandler, Arizona; Phoenix, Arizona; Surprise, Arizona · 322 sites in all
- Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-069.Pivotal-lookingRecruiting
Inmunotek S.L.Industry
NCT07904195 · 250 participants (planned) · Start Apr 15, 2026 · Primary completion Jul 2029
Drug: EP-088_MM09; Placebo · For: Allergic Rhinitis; Allergic Rhinoconjunctivitis; Allergic Asthma
Sites: Covilha, Portugal; Portimão, Portugal; Ponta Delgada, Portugal · 16 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07874815 · 2,136 participants (planned) · Start Nov 2, 2026 · Primary completion Apr 29, 2029
Drug: Ensifentrine; Standard of Care (SOC) · For: Pulmonary Disease, Chronic Obstructive
Sites: Hialeah Gardens, Florida; Loxahatchee Groves, Florida; Valparaiso, Indiana · 7 sites in all
- A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)Pivotal-lookingRecruiting
Generate BiomedicinesIndustry
NCT07276724 · 786 participants (planned) · Start Dec 3, 2025 · Primary completion Dec 2028
Drug: GB-0895; Placebo · For: Severe Asthma
Sites: Northridge, California; Pasadena, California; Rancho Cucamonga, California · 158 sites in all
- Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued TreatmentPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07444567 · 230 participants (planned) · Start Jul 24, 2026 · Primary completion Dec 27, 2029
Drug: Benralizumab · For: Asthma; Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilic Syndrome (HES)
Sites: Aurora, Colorado; Bethesda, Maryland; Ann Arbor, Michigan · 46 sites in all
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) TabletsPivotal-lookingRecruiting
Trevi TherapeuticsIndustry
NCT07868419 · 201 participants (planned) · Start Sep 30, 2026 · Primary completion Aug 2027
Drug: NAL ER; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Tuscaloosa, Alabama; New Britain, Connecticut; Wilmington, Delaware · 16 sites in all
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) TabletsPivotal-lookingRecruiting
Trevi TherapeuticsIndustry
NCT07671911 · 306 participants (planned) · Start Jun 29, 2026 · Primary completion Jun 2028
Drug: NAL ER; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Newport Beach, California; Palm Springs, California; Redding, California · 32 sites in all
- A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07782996 · 370 participants (planned) · Start Aug 27, 2026 · Primary completion May 4, 2029
Drug: GSK5784283; Placebo and 1 more · For: Asthma
Sites: San Diego, California; Miami, Florida; Miami Lakes, Florida · 13 sites in all
- The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With BronchiectasisPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06872892 · 1,755 participants (planned) · Start Jun 9, 2025 · Primary completion Jun 15, 2027
Drug: BI 1291583; Placebo matching BI 1291583 · For: Bronchiectasis
Sites: Birmingham, Alabama; Tucson, Arizona; Newport Beach, California · 474 sites in all
- A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07780656 · 624 participants (planned) · Start Sep 11, 2026 · Primary completion Jul 20, 2029
Drug: GSK5784283; Placebo and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Cape Coral, Florida; Greenacres City, Florida; Miami, Florida · 9 sites in all
- A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe AsthmaPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06023589 · 231 participants (planned) · Start Aug 24, 2023 · Primary completion May 31, 2028
Drug: Tezepelumab · For: Asthma
Sites: Montgomery, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 147 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05776927 · 188 participants (planned) · Start Aug 4, 2026 · Primary completion Dec 30, 2028
Drug: QVM149; Salmeterol Xinafoate / Fluticasone Propionate and 2 more · For: Asthma
Sites: Rosario, Argentina; Strasbourg, France; Wesel, Germany · 27 sites in all
- A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With AsthmaPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05562466 · 200 participants (planned) · Start May 11, 2023 · Primary completion Feb 1, 2028
Drug: QMF149; Budesonide · For: Asthma
Sites: CABA, Argentina; Mendoza, Argentina; Rosario, Argentina · 65 sites in all
- A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07645248 · 110 participants (planned) · Start Sep 1, 2026 · Primary completion Dec 28, 2026
Drug: HFA-152a; HFA-134a · For: Asthma
Sites: Aventura, Florida; Miami, Florida; Naples, Florida · 20 sites in all
- A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe AsthmaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07869043 · 1,100 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 7, 2029
Drug: tilrekimig · For: Asthma
Sites: River Forest, Illinois; Hannibal, Missouri; The Bronx, New York · 12 sites in all
- Phase 3b Study in Patients With Severe Asthma Treated With TezepelumabPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07363642 · 400 participants (planned) · Start Jan 28, 2026 · Primary completion Feb 7, 2028
Drug: Tezepelumab · For: Severe Asthma
Sites: Beijing, China; Binzhou, China; Changsha, China · 75 sites in all
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionPivotal-lookingRecruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT05179876 · 280 participants (planned) · Start May 4, 2022 · Primary completion Jan 31, 2027
Drug: Macitentan; Selexipag and 1 more · For: Hypertension, Pulmonary
Sites: Minsk, Belarus; Leuven, Belgium; Sofia, Bulgaria · 45 sites in all
- A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe DiseasePivotal-lookingRecruiting
Enanta Pharmaceuticals, IncIndustry
NCT07908381 · 860 participants (planned) · Start Oct 19, 2026 · Primary completion Jul 2029
Drug: zelicapavir; Placebo · For: RSV
Sites: Cape Coral, Florida; Miami, Florida; Bluffton, South Carolina · 4 sites in all
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe AsthmaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07772921 · 1,100 participants (planned) · Start Aug 20, 2026 · Primary completion Jun 1, 2029
Drug: tilrekimig · For: Asthma
Sites: Bakersfield, California; Miami, Florida; White Marsh, Maryland · 16 sites in all
- Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.Pivotal-lookingRecruiting
Inmunotek S.L.Industry
NCT07904052 · 250 participants (planned) · Start Feb 24, 2026 · Primary completion Jul 2029
Drug: EP-088_MM09; Placebo · For: Allergic Rhinitis; Allergic Rhinoconjunctivitis; Allergic Asthma
Sites: Coimbra, Portugal; Lisbon, Portugal; Porto, Portugal · 16 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.